Avid Bioservices, Inc. Proposes Transaction With GHO Capital Partners and Ampersand Capital, Encouraging Stockholder Support
Avid Bioservices, Inc. Proposes Transaction With GHO Capital Partners and Ampersand Capital, Encouraging Stockholder Support
Avid Bioservices mailed proxy materials for a stockholder vote on its acquisition by GHO Capital and Ampersand, scheduled for January 30, 2025.
Avid Bioservices寄送了股東投票的代理材料,以批准其被GHO資本和Ampersand收購的事項,投票定於2025年1月30日。
Quiver AI Summary
Quiver AI 概要
Avid Bioservices, Inc. has announced the mailing of definitive proxy materials to its stockholders regarding a planned transaction with GHO Capital Partners and Ampersand Capital Partners, with a Special Meeting set for January 30, 2025, for stockholders to vote on the deal. The company emphasizes that the transaction will provide stockholders with significant cash value of $12.50 per share, representing a substantial premium over recent share prices. The Avid Board of Directors is advocating for a "FOR" vote, stating that the deal maximizes stockholder value while mitigating the risks associated with Avid continuing as a standalone company amidst industry challenges. The announcement also highlights the thorough process undertaken by the Board to assess and negotiate the offer, ensuring it is in the best interests of stockholders.
Avid Bioservices公司已宣佈向其股東郵寄有關與GHO資本和Ampersand資本的擬交易的最終代理材料,並計劃於2025年1月30日進行特別會議,以便股東對該交易進行投票。公司強調,該交易將爲股東提供每股12.50美元的顯著現金價值,代表近期股價的顯著溢價。Avid董事會倡導投票"支持",認爲該交易最大化了股東價值,同時減輕了Avid在行業挑戰中作爲獨立公司的風險。公告還強調了董事會爲評估和談判該報價所進行的全面流程,確保其符合股東的最佳利益。
Potential Positives
潛在的積極因素
- The announced transaction with GHO and Ampersand offers Avid stockholders a significant all-cash value of $12.50 per share, which is a substantial premium over recent closing prices, thereby enhancing stockholder value.
- The Avid Board conducted a thorough and competitive process that resulted in a 19% increase from the initial unsolicited offer, demonstrating their commitment to maximizing stockholder value.
- The transaction effectively de-risks Avid's future as a standalone company amidst industry challenges, providing stockholders with greater certainty regarding the company's financial outlook.
- 與GHO和Ampersand的交易爲Avid股東提供了每股12.50美元的顯著全現金價值,較近期收盤價有顯著溢價,從而提高了股東價值。
- Avid董事會進行了全面且具有競爭力的流程,導致初始的非邀請報價增加了19%,證明了他們最大化股東價值的承諾。
- 該交易有效降低了Avid在行業挑戰中作爲獨立公司的未來風險,爲股東提供了更大的公司財務前景確定性。
Potential Negatives
潛在負面因素
- The recommendation for stockholders to vote "FOR" the transaction suggests that the company's Board perceives navigating a standalone future as too risky or undesirable, indicating potential instability in the company's operational prospects.
- The significant reliance on external capital from GHO and Ampersand raises concerns about the company's ability to sustain operations and growth independently, portraying a lack of confidence in its current business model.
- The acknowledgement of industry-wide macroeconomic headwinds and the need for additional investments highlight challenges the company faces, which may deter investor confidence and suggest underlying weaknesses.
- 建議股東投票"支持"該交易表明公司的董事會認爲獨立未來的前景過於風險或不受歡迎,這表明公司操作前景可能存在不穩定性。
- 對GHO和Ampersand的外部資本的重大依賴引發了人們對公司獨立維持運營和增長能力的擔憂,表現出對其當前業務模型的缺乏信心。
- 對行業範圍內宏觀經濟逆風的認可及對額外投資的需求凸顯了公司面臨的挑戰,這可能會削弱投資者信心並暗示潛在的弱點。
FAQ
常見問題
What is the purpose of Avid Bioservices' special meeting on January 30, 2025?
Avid Bioservices於2025年1月30日舉行的特別會議的目的是什麼?
The meeting will allow stockholders to vote on the pending transaction with GHO Capital Partners and Ampersand Capital Partners.
會議將允許股東對與GHO Capital Partners和Ampersand Capital Partners的待決交易進行投票。
What is the cash value offered to Avid stockholders?
提供給Avid股東的現金價值是多少?
Avid stockholders will receive $12.50 per share in cash, which represents a significant premium.
Avid股東將獲得每股12.50美元的現金,這代表着一個顯著的溢價。
What factors influenced the Avid Board's decision to proceed with the transaction?
是什麼因素影響了Avid董事會決定推進這筆交易?
The Board considered the benefits of immediate cash value, a robust buyer process, and reduced risks of operating independently.
董事會考慮了立即現金價值的好處、強有力的買家流程以及減少獨立運營的風險。
How can Avid stockholders vote on the proposed transaction?
Avid的股東如何對提議的交易進行投票?
Stockholders can vote online, by telephone, or by returning the proxy card they received in the mail.
股東可以通過在線、電話投票或返回他們通過郵寄收到的授權委託卡進行投票。
Where can stockholders find more information about the proxy materials?
股東可以在哪裏找到更多關於授權委託材料的信息?
Stockholders can access the proxy materials through the SEC's website and Avid's investor relations site.
股東可以通過SEC的網站和Avid的投資者關係網站訪問授權委託材料。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明:這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發佈。
$CDMO Insider Trading Activity
$CDMO內部交易活動
$CDMO insiders have traded $CDMO stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
$CDMO的內部人士在過去6個月內在公開市場上交易了$CDMO股票14次。在這些交易中,0次爲購買,14次爲賣出。
Here's a breakdown of recent trading of $CDMO stock by insiders over the last 6 months:
以下是最近6個月內部人士交易$CDMO股票的詳細信息:
- MATTHEW R. KWIETNIAK (Chief Commercial Officer) has traded it 5 times. They made 0 purchases and 5 sales, selling 1,971 shares.
- RICHARD A. RICHIERI (Chief Operations Officer) has traded it 7 times. They made 0 purchases and 7 sales, selling 5,302 shares.
- NICHOLAS STEWART GREEN (President & CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 24,830 shares.
- MATTHEW R. KWIETNIAk(首席商業官)交易了5次。他們進行了0次購買和5次賣出,賣出了1,971股。
- RICHARD A. RICHIERI(首席運營官)交易了7次。他們進行了0次購買和7次賣出,賣出了5,302股。
- NICHOLAS STEWARt GREEN(總裁兼首席執行官)交易了2次。他們進行了0次購買和2次賣出,賣出了24,830股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟蹤內部交易,請查看Quiver Quantitative的內部交易儀表。
$CDMO Hedge Fund Activity
$CDMO對沖基金活動
We have seen 84 institutional investors add shares of $CDMO stock to their portfolio, and 88 decrease their positions in their most recent quarter.
我們看到84家機構投資者在最近一個季度將$CDMO股票新增到他們的投資組合中,而88家則減少了他們的持倉。
Here are some of the largest recent moves:
以下是最近的一些重大變動:
- 12 WEST CAPITAL MANAGEMENT LP removed 3,645,844 shares (-100.0%) from their portfolio in Q3 2024
- FIRST LIGHT ASSET MANAGEMENT, LLC added 2,771,853 shares (+inf%) to their portfolio in Q3 2024
- COLISEUM CAPITAL MANAGEMENT, LLC removed 1,746,588 shares (-100.0%) from their portfolio in Q3 2024
- NEWTYN MANAGEMENT, LLC removed 1,500,000 shares (-100.0%) from their portfolio in Q2 2024
- EMERALD ADVISERS, LLC added 1,448,916 shares (+inf%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 1,142,756 shares (+42.8%) to their portfolio in Q3 2024
- EMERALD MUTUAL FUND ADVISERS TRUST added 1,050,308 shares (+inf%) to their portfolio in Q3 2024
- 12 WESt CAPITAL 資產管理 LP 在2024年第三季度從他們的投資組合中移除了3,645,844股(-100.0%)
- FIRSt LIGHt 資產管理, LLC 在2024年第三季度向他們的投資組合中增加了2,771,853股(+inf%)
- COLISEUm CAPITAL 資產管理, LLC 在2024年第三季度從他們的投資組合中移除了1,746,588股(-100.0%)
- NEWTYN 資產管理, LLC 在2024年第二季度從他們的投資組合中移除了1,500,000股(-100.0%)
- Emerald 顧問, LLC 在2024年第三季度向他們的投資組合中增加了1,448,916股(+inf%)
- POINT72 資產管理, L.P. 在2024年第三季度向他們的投資組合中增加了1,142,756股(+42.8%)
- Emerald 共同基金顧問信託在2024年第三季度向他們的投資組合中增加了1,050,308股(+inf%)
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要跟蹤對沖基金的股票投資組合,請查看Quiver Quantitative的機構持有情況儀表。
Full Release
完整發佈
TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has commenced mailing definitive proxy materials and a letter to stockholders in connection with its pending transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners ("Ampersand").
加利福尼亞州圖森,2024年12月18日(GLOBE NEWSWIRE)-- Avid Bioservices, Inc. (納斯達克: CDMO)("Avid"或"公司"),一家專注於提高患者生活的生物製品合同開發和製造組織("CDMO"),通過爲生物技術和藥品公司提供高質量的開發和製造服務,今天宣佈已經開始向股東寄送決定性代理材料和一封與其與GHO Capital Partners LLP("GHO")及Ampersand Capital Partners("Ampersand")的待交易相關的信函。
The Special Meeting to vote on the transaction is scheduled for January 30, 2025, and Avid stockholders of record as of December 11, 2024, are eligible to vote at the Special Meeting.
特別會議投票通過此交易的時間定於2025年1月30日,2024年12月11日的Avid股東記錄有資格在特別會議上投票。
The letter to stockholders highlights:
發給股東的信函強調了:
-
How the transaction with GHO and Ampersand delivers significant, immediate and certain cash value to Avid stockholders;
-
The robust process conducted by the Avid Board of Directors maximizes value for stockholders; and
-
The transaction de-risks for stockholders Avid's future as a standalone company.
-
與GHO和Ampersand的交易爲Avid股東提供了顯著、立即和確定的現金價值;
-
Avid董事會進行的穩健流程最大化了股東的價值;並且
-
該交易降低了股東Avid作爲獨立公司的未來風險。
The full text of the letter follows:
信件的全文如下:
December 18, 2024
2024年12月18日
Dear Fellow Avid Bioservices Stockholders,
親愛的Avid Bioservices股東,
We are reaching out to let you know that you need to take action to realize the full value of your Avid Bioservices investment. Specifically, you need to
vote FOR
the pending transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners ("Ampersand").
我們聯繫您是想讓您知道,您需要採取行動,以實現您在Avid Bioservices投資的全部價值。具體來說,您需要
投票贊成
與GHO Capital Partners LLP("GHO")和Ampersand Capital Partners("Ampersand")的待決交易。
We firmly believe the transaction is in the best interest of all Avid stockholders as it:
我們堅信該交易符合所有Avid股東的最佳利益,原因如下:
-
Provides significant, immediate and certain cash value to Avid stockholders;
-
Reflects a robust process conducted by the Board to ensure we are maximizing value; and
-
De-risks for stockholders Avid's future as a standalone company.
-
爲Avid股東提供顯著、即時且確定的現金價值;
-
反映了董事會進行的穩健流程,以確保我們最大化價值;並且
-
降低了Avid作爲一家獨立公司的未來風險,爲股東提供保障。
Our Board of Directors unanimously recommends stockholders to vote "
FOR
" the transaction today.
我們的董事會一致推薦股東投票"
支持
"今天的交易。
Delivering Significant, Immediate and Certain Cash Value to Avid Stockholders
爲Avid股東提供顯著、即時和確定的現金價值
The
$12.50 per share all-cash consideration
provides a
significant premium
to Avid stockholders across multiple time periods at a
compelling valuation
.
這
每股現金對價$12.50
提供給
顯著的溢價
給Avid股東在多個時間段的
有吸引力的估值
.
$12.50 Per share in cash |
$1.1 Billion Enterprise value |
13.8% Premium to Avid's closing share price of $10.98 on November 6, 2024, the last full trading day prior to the transaction announcement (the "Unaffected Date") |
63.8% premium to the Company's closing price of $7.63 on June 4, 2024, the last trading day prior to GHO and Ampersand's June 5 Initial Proposal |
21.9% premium to the Company's 20-day VWAP ending on the Unaffected Date |
24.4% premium to the Company's 90-day VWAP ending on the Unaffected Date |
50.1% premium to the Company's 6-month VWAP ending on the Unaffected Date |
207.1% premium to the Company's 52-week low ending on the Unaffected Date |
6.5x multiple to management forecasted FY2025E revenue |
$12.50 每股現金 |
$11億 企業價值 |
13.8% 相較於Avid在2024年11月6日的收盤價$10.98,交易公告前的最後一個完整交易日("未受影響日期") |
63.8% 相較於公司在2024年6月4日的收盤價$7.63,GHO和Ampersand的首次提案日期爲6月5日,之前的最後一個交易日 |
21.9% 相較於公司在未受影響日期的20天加權平均價格 |
24.4% 與公司在未受影響日期結束的90天加權平均股價相比溢價 |
50.1% 與公司在未受影響日期結束的6個月加權平均股價相比溢價 |
207.1% 與公司在未受影響日期結束的52周最低價相比溢價 |
6.5倍 相對於管理層預測的2025財年營業收入的倍數 |
The Avid Board Conducted a Competitive Process to Maximize Value
Avid董事會進行了一項競爭性程序,以最大化價值
By the Numbers
通過數字
The Avid Board of Directors is committed to maximizing the value for Avid stockholders. That is why the Board conducted a thoughtful, exhaustive and deliberate process that thoroughly tested buyer interest, with support from its legal and financial advisors, after receiving an initial unsolicited offer from GHO and Ampersand to acquire the Company for $10.50 per share in cash. As detailed in our proxy, our Board and management team know our industry and the players in it well, having previously explored other potential strategic transactions and conducted diligence as part of those efforts. We did not proceed with those potential alternatives as our Board did not believe they created the most value for stockholders. When GHO and Ampersand made initial offers to acquire the Company, the Board reviewed them and rejected them as not sufficiently valuing the Company. The Board considered the Company's standalone prospects, the risks and uncertainties of continuing to execute its standalone plans and the ability of Avid stockholders to adequately recognize the future value of Avid's reasonable expectations for growth. The Board also conducted a process, which included outreach to at least 24 most likely strategic and financial buyers to gauge interest in a potential sale of the company. That process resulted in confidential discussions with seven parties and culminated with non-binding proposals from GHO and Ampersand and another party. After a period of back-and-forth communication with each party, the Board determined to proceed with GHO's and Ampersand's increased proposal. Ultimately, the process and negotiations with GHO and Ampersand resulted in five improvements to price and a 19% price improvement from the original unsolicited offer. The Board is confident that this robust process has led to the value maximizing outcome for stockholders. |
12 Board meetings since receipt of initial unsolicited offer to discuss the process |
|
24 Most likely strategic and financial buyers engaged to explore interest in acquiring the Company |
||
5 Improvements to the GHO and Ampersand offer resulting from the robust process and negotiations |
||
19% Price improvement from the initial unsolicited offer |
Avid董事會致力於爲Avid股東最大化價值。這就是爲什麼董事會在收到GHO和Ampersand提出的以每股10.50美元現金收購公司的初步無條件報價後,進行了深思熟慮、全面且謹慎的流程,充分測試買方的興趣,並得到了其法律和財務顧問的支持。 正如我們代理文件中詳細說明的,我們的董事會和管理團隊非常了解我們的行業及其參與者,之前曾探討過其他潛在的戰略交易,並在這些努力中進行了盡職調查。我們沒有推進這些潛在的替代方案,因爲我們的董事會並不認爲它們爲股東創造了最大的價值。 當GHO和Ampersand提出收購公司初步報價時,董事會審查了這些報價,並認爲它們對公司的價值評估不夠充分而拒絕了它們。董事會考慮了公司的獨立前景、繼續執行其獨立計劃的風險與不確定性,以及Avid股東能夠充分認識Avid合理增長預期的未來價值的能力。 董事會還進行了一個流程,其中包括與至少24名最有可能的戰略和財務買家的聯繫,以評估對公司潛在出售的興趣。該流程導致與七方的保密討論,並最終收到了來自GHO、Ampersand和另一方的非約束性提案。 經過一段時間與各方的反覆溝通,董事會決定接受GHO和Ampersand的增價提案。 最終,與GHO和Ampersand的流程和談判帶來了五項價格改善,較最初的非請約報價提升了19%。 董事會對這一強有力的流程所帶來的結果充滿信心。 創造了最大化價值的結果 面向股東。 |
12 自收到初始非請求報價以來的董事會會議以討論這一過程 |
|
24 最有可能參與收購公司的戰略和財務買家 |
||
5 由於強有力的流程和談判,對GHO和Ampersand報價的改進 |
||
19% 比最初的非請求報價有所改善的價格 |
The Transaction De-Risks Avid's Future as a Standalone Company
這筆交易降低了Avid作爲獨立公司的風險
We are incredibly proud of the progress that we have made as a public company. That said, in evaluating the transaction, our Board considered factors that could impact our standalone financial and operating results going forward. These included, among others:
我們爲作爲上市公司取得的進展感到無比自豪。儘管如此,在評估此次交易時,我們的董事會考慮了可能影響我們獨立財務和運營結果的因素。這些因素包括但不限於:
-
Industry-wide Macroeconomic Headwinds:
There are a range of challenges facing the biologics manufacturing industry, including uncertainty around the recovery in biotech funding, increased volatility resulting from escalating political and global trade tensions that could disrupt supply chains, and increasing competition.
-
Additional Investments Needed:
While Avid has made a number of strategic investments in the business over the last several years, more is needed to capitalize on the Company's growth potential.
-
Updated Go-Forward Growth Expectations as a Public Company:
As part of its review of potential strategic alternatives, the Board requested that Moelis prepare a financial analysis on Avid management's probability-adjusted five-year plan for fiscal years 2025 through 2029. That review indicated that the Company's growth prospects were below its own previous guidance as well as analysts' consensus. Therefore, the Board determined that the transaction with GHO and Ampersand represented a value maximizing outcome for Avid stockholders, providing superior risk-adjusted value and certainty of execution. We encourage stockholders to read more about these financial projections and the financial analysis conducted by our financial advisor in our supplemental proxy filing materials.
-
行業整體宏觀經濟逆風:
生物製品製造行業面臨一系列挑戰,包括對生物技術資金回升的不確定性、因政治和全球貿易緊張局勢升級造成的波動性增加而可能擾亂供應鏈,及日益增強的競爭。
-
需要更多的投資:
雖然Avid在過去幾年中對業務進行了多項戰略投資,但爲了充分挖掘公司的增長潛力,仍需要更多的投資。
-
作爲上市公司更新未來增長預期:
作爲對潛在戰略選擇的審查的一部分,董事會要求Moelis準備一份關於Avid管理層概率調整的五年計劃(財政年度2025至2029年)的財務分析。該審查表明,公司增長前景低於其自身以前的指導以及分析師的共識。因此,董事會決定與GHO和Ampersand的交易代表了爲Avid股東創造價值的最佳結果,提供了更優的風險調整價值和執行確定性。我們鼓勵股東閱讀我們的補充委託申請文件中有關這些財務預測和我們財務顧問進行的財務分析的更多信息。
We believe the transaction pays stockholders
fair value
for the investments Avid has made to date and eliminates for stockholders the execution risk of Avid continuing to operate on a standalone basis.
我們相信該交易爲股東支付了
公允價值
Avid迄今爲止所做的投資,並消除了Avid繼續獨立運營所帶來的執行風險。
YOUR VOTE MATTERS: TAKE ACTION AND VOTE TODAY
您的投票至關重要:立即採取行動,投票今天
We strongly encourage you to get your vote "
FOR
" the transaction today so, you can obtain significant, immediate and certain value for your Avid investment.
我們強烈鼓勵您參與投票"
支持
" 今天的交易使您可以爲您的Avid投資獲得顯著、立即和確定的價值。
Regardless of how many shares you own
, your vote matters.
You can vote online, by phone or by signing and returning the proxy card that was mailed with the Company's definitive proxy materials.
無論您擁有多少股份
,您的投票很重要。
您可以在線投票、通過電話投票或簽署並返回隨公司最終委託材料郵寄的代理卡。
Thank you for your continued support.
感謝您一直以來的支持。
Sincerely,
致以誠摯的問候,
The Avid Bioservices Board of Directors
Avid Bioservices董事會
The Avid Board of Directors Unanimously Recommends that Avid Stockholders Vote "FOR" the proposed transaction with GHO and Ampersand. Vote TODAY online, by telephone or by signing and returning the enclosed proxy card. If you have questions or need assistance voting your shares, please contact: MacKenzie Partners, Inc. 7 Penn Plaza New York, New York 10001 U.S. & Canada Toll-Free: 1-800-322-2885 Elsewhere Call Collect: +1-212-929-5500 Or Email: proxy@MacKenziePartners.com |
Avid董事會一致推薦Avid股東投票"支持"與GHO和Ampersand的擬議交易。 請今天通過在線、電話或簽署並返回隨附的委託書卡進行投票。 如果您有任何問題或需要幫助投票您的股份,請聯繫: 麥肯齊合夥公司 7 Penn Plaza 紐約,紐約 10001 美國與加拿大免費電話:1-800-322-2885 其他地區請撥打收費電話:+1-212-929-5500 或者 電子郵件:proxy@MacKenziePartners.com |
Advisors
顧問
Moelis & Company LLC is serving as exclusive financial advisor to Avid, and Cooley LLP is serving as legal counsel to Avid.
Moelis & Company LLC擔任Avid的獨家財務顧問,Cooley LLP擔任Avid的法律顧問。
About Avid Bioservices, Inc.
關於Avid Bioservices, Inc.
Avid Bioservices (NASDAQ: CDMO) is a dedicated CDMO focused on development and CGMP manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization.
Avid Bioservices (納斯達克: CDMO)是一家專注於生物製品開發和CGMP製造的專業CDMO。公司爲生物技術和生物製藥行業提供全面的工藝開發、CGMP臨牀和商業製造服務。Avid在生物製品生產方面擁有超過30年的經驗,其服務包括CGMP臨牀和商業藥物活性物質製造、大宗包裝、放行和穩定性測試以及監管提交支持。對於早期項目,公司提供多種工藝開發活動,包括電芯開發、上游和下游開發與優化、分析方法開發、測試和表徵。我們的服務範圍從獨立的工藝開發項目到全面的開發和製造項目,直至商業化。
ADDITIONAL INFORMATION AND WHERE TO FIND IT
附加信息及其來源
The Company has filed a proxy statement with the U.S. Securities and Exchange Commission ("SEC") with respect to a special meeting of stockholders to be held in connection with the proposed transaction. Promptly after filing the definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the proposed transaction. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the preliminary and definitive versions of the proxy statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the proposed transaction at the SEC's website ( Copies of the preliminary and definitive versions of the proxy statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the proposed transaction will also be available, free of charge, at the Company's investor relations website ( The information provided on, or accessible through, our website is not part of this press release, and therefore is not incorporated herein by reference.
公司已向美國證券交易委員會("SEC")提交了關於擬交易的特別股東會議的代理聲明。在向SEC提交最終的代理聲明後,公司將向每位有權在特別會議上投票的股東郵寄最終的代理聲明和代理卡。督促股東閱讀代理聲明(包括任何修訂或補充內容)以及公司將與SEC一起提交的任何其他相關文件,因爲它們將包含重要信息。股東可以免費獲得與擬交易相關的代理聲明的初步和最終版本、任何修訂或補充內容及公司與SEC一起提交的任何其他相關文件,訪問SEC的網站(與擬交易相關的代理聲明的初步和最終版本、任何修訂或補充內容及公司與SEC一起提交的任何其他相關文件也可在公司的投資者關係網站上免費獲得(在我們網站上提供或可通過網站訪問的信息不構成本新聞稿的一部分,因此不在此處引用。
PARTICIPANTS IN THE SOLICITATION
招募參與者
The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding the Company's directors and executive officers is available in the Company's proxy statement for the 2024 annual meeting of stockholders, which was filed with the SEC on August 28, 2024 (the "Annual Meeting Proxy Statement"). Please refer to the sections captioned "Security Ownership of Certain Beneficial Owners, Directors and Management," "Director Compensation," and "Executive Compensation-Outstanding Equity Awards at Fiscal Year-End" in the Annual Meeting Proxy Statement. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the Annual Meeting Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC: Form 4, filed by Nicholas Stewart Green on October 11, 2024, Form 4, filed by Richard A. Richieri on October 11, 2024, Form 4, filed by Matthew R. Kwietniak on October 11, 2024, and Form 4, filed by Matthew R. Kwietniak on October 15, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the definitive proxy statement and other relevant materials to be filed with the SEC in connection with the proposed transaction when they become available. Free copies of the Annual Meeting Proxy Statement, the definitive proxy statement related to the proposed transactions and such other materials may be obtained as described in the preceding paragraph.
公司及其某些董事、高級職員和員工可能被視爲擬交易代理的招攬參與者。關於公司董事和高級職員的信息在公司於2024年8月28日向SEC提交的2024年度股東大會的代理聲明中提供(「年度股東大會代理聲明」)。請參考年度股東大會代理聲明中「特定受益所有者、董事及管理層的證券持有情況」、「董事薪酬」和「高管薪酬-財年末未償還股權獎勵」章節。若這些參與者在公司證券的持有情況自年度股東大會代理聲明中所描述的金額有所變動,這些變動已在向SEC提交的初步受益所有權報表(Form 3)或所有權變更報表(Form 4)中反映:Nicholas Stewart Green於2024年10月11日提交的Form 4,Richard A. Richieri於2024年10月11日提交的Form 4,Matthew R. Kwietniak於2024年10月11日提交的Form 4,以及Matthew R. Kwietniak於2024年10月15日提交的Form 4。關於代理招攬參與者的其他信息及其直接和間接利益的描述,按照證券持有情況或其他方式,將包含在最終的代理聲明及屆時將向SEC提交的與擬交易相關的其他材料中。年度股東大會代理聲明、與擬交易相關的最終代理聲明以及上述其他材料的免費副本可按照前一段的描述獲得。
FORWARD-LOOKING STATEMENTS
前瞻性聲明
This communication contains "forward-looking statements" which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company's expectations, intentions or strategies regarding the future, or the completion or effects of the proposed sale of Avid to GHO and Ampersand. In some cases, these statements include words like: "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed transaction that could delay the consummation of the proposed transaction or cause the parties to abandon the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in connection with the proposed transaction; the possibility that the Company's stockholders may not approve the proposed transaction; the risk that the parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company's common stock; the risk of any unexpected costs or expenses resulting from the proposed transaction; the risk of any litigation relating to the proposed transaction; and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in the Company's most recent filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the quarter ended October 31, 2024 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at
本次溝通包含「前瞻性聲明」,其中包括但不限於所有與歷史或當前事實無關的陳述,例如關於公司對未來的期望、意圖或策略的陳述,或關於將Avid出售給GHO和Ampersand的提議交易的完成或影響。在某些情況下,這些聲明包括如:「可能」、「可能會」、「將」、「能夠」、「會」、「應該」、「期望」、「打算」、「計劃」、「目標」、「預期」、「相信」、「估計」、「預測」、「項目」、「潛在」、「繼續」和「正在進行」等詞彙,或這些術語的否定形式,或其他比較的術語,以識別關於未來的聲明。這些前瞻性聲明受到1995年《私人證券訴訟改革法案》下的安全港條款的保護。公司的期望和信念可能不會實現。實際結果和結果可能與這些前瞻性聲明所設想的結果有實質性差異,原因包括不確定性、風險和情況變化,包括但不限於與以下事項相關的風險和不確定性:所需政府和監管批准的時機、接收及條款和條件,可能會延遲提議交易的完成或導致各方放棄提議交易;任何事件、變化或其他情況的發生,可能導致與提議交易相關的併購協議的終止;公司股東可能不同意提議交易的風險;併購協議各方可能無法及時滿足提議交易條件的風險;由於提議交易導致的對管理時間的干擾風險;與提議交易相關的任何公告可能對公司普通股的市場價格產生不利影響的風險;因提議交易產生的任何意外成本或費用的風險;與提議交易相關的任何訴訟的風險;及提議交易及其公告可能對公司保留和招聘關鍵人員的能力、與客戶、供應商、合作伙伴、員工、股東及其他商業關係的關係以及其經營成果和業務整體產生不利影響的風險。導致實際結果和結果可能與前瞻性聲明所設想的結果存在實質性差異的其他風險和不確定性已包含在公司最近提交給SEC的文件中的「風險因素」標題下,以及公司截至2024年10月31日的季度報告(Form 10-Q)及不時提交的任何後續Form 10-K、Form 10-Q或Form 8-K報告中,並可在
The forward-looking statements included in this information statement are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
本信息聲明中包含的前瞻性陳述僅在本日期時有效。公司不承擔任何義務,也不打算更新這些前瞻性陳述,法律要求的情況除外。
Contacts:
聯繫方式:
Avid Bioservices
Avid Bioservices
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
斯蒂芬妮·迪亞斯(投資者)
Vida戰略合作伙伴
415-675-7401
sdiaz@vidasp.com
Tim Brons
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
TIM Brons
Vida戰略合作伙伴
415-675-7402
tbrons@vidasp.com
Bob Marese / John Bryan (For Voting Inquiries)
MacKenzie Partners, Inc.
1-800-322-2885
proxy@MacKenziePartners.com
鮑勃·馬雷斯 / 約翰·布萊恩(投票查詢)
麥肯齊合夥公司
1-800-322-2885
proxy@MacKenziePartners.com
Aaron Palash / Allison Sobel (Media)
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
亞倫·帕拉什 / 艾莉森·索貝爾(媒體)
喬爾·弗蘭克,威爾金森·布里默·凱徹
(212) 355-4449